Product information and disease descriptionProduct descriptionProduct information
Co-prescribed/Concomitant therapies
7 evidence topics · 10 sources
Discontinuation of prohibited medications before dosing in the phase 3 trials
Antidepressant discontinuation during screening in the phase 2b trial
“Data from 233 participants with treatment-resistant depression (TRD) who received 25 mg, 10 mg, or 1 mg of investigational drug COMP360 psilocybin (a proprietary, pharmaceutical-grade synthetic psilocybin formulation, developed by the sponsor, Compass Pathfinder Ltd.), administered with psychological support, were compared for groups of participants who either discontinued one or more antidepressant drugs during screening or entered the trial antidepressant drug free.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Suicidality was comparable between groups at Baseline.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Withdrawal of antidepressant, antipsychotic, and mood-stabilizing drugs in the PsiDeR trial
Adjunctive SSRI: COMP360 25 mg with an ongoing SSRI
“Participants were taking a locally approved therapeutic dose of a single SSRI with at least 75% adherence for a minimum of six weeks prior to taking part and were asked to continue this treatment for the duration of the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“All participants continued their SSRI medication throughout the follow-up period and to the end of the study (Week 3); two participants on escitalopram increased their dose (10–20 mg) during the study.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Twelve (63.2%) participants had a TEAE, most of which were mild and resolved on the day of onset.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“There were no serious TEAEs or indication of increased suicidal ideation or behavior.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Larger, comparator-controlled trials are necessary to understand if this paradigm can optimize treatment-outcome where antidepressant drug withdrawal would be problematic.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Adjunctive antidepressant permitted in the company's PTSD trial
Concomitant psychotherapy
Rescue medication during an administration session
“An AE of substance induced psychotic disorder was reported for a participant who became behaviourally disinhibited during the acute drug experience.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“After a medical assessment, 2.5 mg oromucosal midazolam was administered.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The participant recovered with no sequelae and was discharged 11 h after receiving the study intervention.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote